Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

by Feyerabend, Susan , Iacovelli, Roberto , Sverrisdóttir, Ásgerður , de Wit, Ronald , Ozatilgan, Ayse , Fizazi, Karim , Melichar, Bohuslav , Castellano, Daniel , de Bono, Johann , Bamias, Aristotelis , Tombal, Bertrand , Eymard, Jean-Christophe , Helissey, Carole , Theodore, Christine , Sternberg, Cora N , Carles, Joan , Geffriaud-Ricouard, Christine , Wülfing, Christian , Kramer, Gero

in Aged / Aged, 80 and over / Analgesics / Androgen Antagonists - administration & dosage / Androgen Antagonists - adverse effects / Androgens / Androstenes - administration & dosage / Androstenes - adverse effects / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Cancer therapies / Castration / Colony-stimulating factor / Death / Granulocyte colony-stimulating factor / Humans / Infusions, Intravenous / Kaplan-Meier Estimate / Leukocytes (granulocytic) / Male / Metastases / Metastasis / Middle Aged / Pain / Patients / Phenylthiohydantoin - administration & dosage / Phenylthiohydantoin - adverse effects / Phenylthiohydantoin - analogs & derivatives / Prednisone / Prednisone - administration & dosage / Progression-Free Survival / Prostate cancer / Prostate-specific antigen / Prostatic Neoplasms, Castration-Resistant - drug therapy / Prostatic Neoplasms, Castration-Resistant - mortality / Safety / Survival / Taxoids - administration & dosage / Taxoids - adverse effects / Working groups

2019

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

2019

Confirm

Do you wish to request the book?

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

2019

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

Feyerabend, Susan,

Iacovelli, Roberto,

Sverrisdóttir, Ásgerður,

de Wit, Ronald,

Ozatilgan, Ayse,

Fizazi, Karim,

Melichar, Bohuslav,

Castellano, Daniel,

de Bono, Johann,

Bamias, Aristotelis,

Tombal, Bertrand,

Eymard, Jean-Christophe,

Helissey, Carole,

Theodore, Christine,

Sternberg, Cora N,

Carles, Joan,

Geffriaud-Ricouard, Christine,

Wülfing, Christian,

Kramer, Gero

2019

Overview

A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling–targeted agent in extending imaging-based progression-free survival, overall survival, and PSA response.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Aged

/ Aged, 80 and over

/ Analgesics

/ Androgen Antagonists - administration & dosage

/ Androgen Antagonists - adverse effects

/ Androgens

/ Androstenes - administration & dosage